Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)

CAPS Rating: 4 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar Perdrix (< 20) Submitted: 9/19/2011 9:25:07 AM : Outperform Start Price: $1.85 AEZS Score: -84.12

A few products comming out with important results by the end of the year

Featured Broker Partners


Advertisement